Last reviewed · How we verify
Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To An Alprazolam Sublingual Tablet
This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing sublingual formulation.
Details
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
|---|---|
| Phase | Phase 1 |
| Status | WITHDRAWN |
| Start date | 2011-04 |
| Completion | 2011-06 |
Conditions
- Healthy
Interventions
- alprazolam commercial sublingual formulation
- alprazolam test sublingual tablet
Primary outcomes
- Alprazolam bioavailability as assessed from the area under the concentration-time curve (AUC) — 11 days
- Alprazolam bioavailability as assessed by peak concentration (Cmax) — 11 days